A new multitech bioprinter for high precision triple negative breast cancer modeling

Abstract Bioprinting is a manufacturing method that enables the precise deposition of bioinks in the three-dimensional environment based on a digitally created model. In cancer modelling, bioprinting has the potential to produce complex, multicellular, and reproducible biological constructs. However, optimizing bioprinting processes remains a significant challenge. This study presents a new multi-technology bioprinter concept that combines the Extrusion-Based bioprinting (EBB) with Digital Light Processing (DLP), enabling the fabrication of highly accurate biological constructs. To validate the technology, various process parameters –including feed rate, flow rate and DLP curing time– were analysed. Hydrogels composed of a seaweed polysaccharide and gelatin methacryloyl (Bioink 1) and a tuber-derived polysaccharide and gelatin methacryloyl (Bioink 2) with MDA-MB-231 or MDA-MB-468 cells were prepared. Prior to printing, cytocompatibility was assessed through an MTT assay. Dimensional accuracy varying flow rate and feed rate was assessed on a bioink with similar viscosity. Based on previous results, Bioink 1 and MDA-MB-231 were used to print constructs with varying process parameters and cell viability was assessed. Results indicate that cytocompatibility is influenced by cell type, bioink composition and culture duration, while printing parameters have no relevant impact on cell viability, although lower feed rates slightly influence cell survival. Consequently, this study demonstrates that the optimization of printing parameters can significantly improve cell viability and structural integrity, highlighting the potential of this approach as a promising tool for advancing cancer modeling.